Article Text

This article has a correction. Please see:

other Versions

PDF
Mode of action of abatacept in rheumatoid arthritis patients having failed TNF blockade: a histological, gene expression and dynamic MRI pilot study
  1. Maya H Buch (m.buch{at}leeds.ac.uk)
  1. University of Leeds, United Kingdom
    1. David L. Boyle (dboyle{at}ucsd.edu)
    1. University of California, Uzbekistan
      1. Sanna Rosengren (srosengren{at}ucsd.edu)
      1. University of California, Uzbekistan
        1. Benazir Saleem (benazir_saleem{at}yahoo.co.uk)
        1. University of Leeds, United Kingdom
          1. Richard J Reece (richard.reece{at}cht.nhs.uk)
          1. University of Leeds, United Kingdom
            1. Laura A Rhodes (lar{at}medphysics.leeds.ac.uk)
            1. University of Leeds, United Kingdom
              1. Aleksandra Radjenovic
              1. University of Leeds, United Kingdom
                1. Anne English (a.a.english{at}leeds.ac.uk)
                1. University of Leeds, United Kingdom
                  1. Haiqing Tang
                  1. Bristol-Myers Squibb, United States
                    1. George Vratsanos (george.vratsanos{at}bms.com)
                    1. Bristol-Myers Squibb, United States
                      1. Philip O'Connor (philip.o'connor{at}leedsth.nhs.uk)
                      1. Leeds General Infirmary, United Kingdom
                        1. Gary S Firestein (gfirestein{at}ucsd.edu)
                        1. UCSD School of Medicine, United States
                          1. Paul Emery (p.emery{at}leeds.ac.uk)
                          1. University of Leeds, United Kingdom

                            Abstract

                            Objectives: Abatacept is the only agent currently approved to treat rheumatoid arthritis (RA) that targets the co-stimulatory signal required for full T-cell activation. There have been no studies of its effect on the synovium, the primary site of pathology. The aim of this study was to determine the synovial effect of abatacept in patients with RA and an inadequate response to tumor necrosis factor-α (TNF-α) blocking therapy.

                            Methods: This first mechanistic study incorporated both dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and arthroscopy-acquired synovial biopsies before and 16 weeks after therapy, providing tissue for immunohistochemistry and quantitative real-time polymerase chain reaction (PCR) analyses.

                            Results: Sixteen patients (13 female) were studied; all had previously failed TNF-α blocking therapy. Fifteen patients completed the study. Synovial biopsies showed a small reduction in cellular content, which was significant only for B cells. The quantitative PCR showed a reduction in expression for most inflammatory genes (Wald statistic of p < 0.01 indicating a significant treatment effect), with particular reduction (95% CI) in interferon-γ of -52% (-73, -15, p < 0.05); this correlated well with MRI improvements. In addition, favourable changes in the osteoprotegerin and receptor activator of nuclear factor κB levels were noted. DCE-MRI showed a reduction of 15–40% in MRI parameters.

                            Conclusion: These results indicate that abatacept reduces the inflammatory status of the synovium without disrupting cellular homeostasis. The reductions in gene expression influence bone positively and suggest a basis for the recently demonstrated radiologic improvements that have been seen with abatacept treatment in patients with RA.

                            Statistics from Altmetric.com

                            Request permissions

                            If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

                            Linked Articles

                            • Miscellaneous
                              BMJ Publishing Group Ltd and European League Against Rheumatism